News

Achema with bioeconomy highlights
Enlarge image

BusinessGermany

Achema with bioeconomy highlights

22.06.2012 - Finale at ACHEMA: The world's biggest fair for chemical engineering, biotechnology and environmental protection delivers its final day.

Frankfurt – The fair brings together more than 180,000 participants and 3,770 exhibitors from 56 countries. Hot topics at ACHEMA 2012 are energy and resources. With BiobasedWorld, the organisers have introduced a special industrial biotechnology and biomass processing focus, mirroring how the knowledge-based bioeconomy has started to transform the chemical industry. The bioeconomy is not only a special focus amongst exhibitors, but was also covered by its own "BiobasedWorld" conference.

The importance of the subject was highlighted by a group of 30 science and industry experts from Germany presenting  the "Roadmap Biorefineries". This paper, worked out on behalf of the Federal Government , includes a SWOT analysis on the potential of available biorefinery technologies as well as fields where further research and development efforts are necessary by the year 2030.

Georg Schütte, State Secretary in the Federal Ministry for Education and Research, also introduced three strategic alliances in industrial biotechnology. In these alliances, partners from industry and research from a variety of industry branches work together to foster “biologisation” of industry and to deliver novel biobased products. The alliance "ZeroCarbon Footprint" , coordinated by energy giant RWE Power AG , will have a total volume of €46m, from which the half is financed by public money. It focuses on using carbon-rich waste streams as a basis for novel biotech products. The alliance "Functionalisation of polymers", coordinated by enzyme specialist Evocatal, will see the government und the respective industry partners investing €8m in total. The cosmetics and nutraceuticals alliance "NatLifE", coordinated by BRAIN AG, will have a total volume of €30m.

http://www.european-biotechnology-news.com/news/news/2012-02/achema-with-bioeconomy-highlights.html

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 One of the biggest pharma mergers of the year has been called off. Abbvie has dropped plans to acquire UK’s Shire following new US tax rules.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%

FLOP

  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%

TOP

  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%

FLOP

  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%

TOP

  • SANTHERA82.40 CHF2139.1%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR141.3%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.6%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 19.10.2014